Cytek Biosciences, Inc. cash flow statement
In fiscal 2025, Cytek Biosciences, Inc.'s operations generated −$4.7m of cash; it spent $4.1m on capital projects, leaving free cash flow of −$8.8m. It returned $15.1m through buybacks.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 15 | 5 | −12 | 5 | 25 | −5 | −6 |
| Depreciation and amortisation | 1 | 1 | 2 | 6 | 7 | 8 | 6 |
| Stock-based pay | 1 | 7 | 17 | 22 | 27 | 25 | 21 |
| Capital spending | 2 | 4 | 10 | 5 | 4 | 4 | 6 |
| Free cash flow | 14 | 0 | −22 | 1 | 22 | −9 | −12 |
| Free cash flow after stock pay | 13 | −6 | −39 | −21 | −5 | −33 | −33 |
| Share buybacks | — | 0 | 0 | 44 | 22 | 15 | −0 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13 | 2 | −0 | 0 | −4 | −1 | −3 | 1 |
| Depreciation and amortisation | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 |
| Stock-based pay | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 5 |
| Capital spending | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 |
| Free cash flow | 12 | 1 | −1 | −1 | −5 | −2 | −5 | −1 |
| Free cash flow after stock pay | 5 | −6 | −8 | −8 | −10 | −7 | −10 | −6 |
Compare with peers
- Maravai Lifesciences Holdings, Inc. cash flow
- Cryoport, Inc. cash flow
- Mesa Laboratories Inc cash flow
- Grail, Inc. cash flow
- Schrodinger, Inc. cash flow
Head to head: CTKB vs MRVICTKB vs CYRXCTKB vs MLAB
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies